These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

544 related items for PubMed ID: 19276314

  • 1. Human papillomavirus quadrivalent vaccine: a look behind the numbers.
    Flaherty DK, Alkhateeb FM.
    Ann Pharmacother; 2009 Apr; 43(4):740-4. PubMed ID: 19276314
    [Abstract] [Full Text] [Related]

  • 2. Human papillomavirus vaccine for genotypes 6, 11, 16 and 18: new drug. Cervical cancer prevention: high hopes...
    Prescrire Int; 2007 Jun; 16(89):91-4. PubMed ID: 17582921
    [Abstract] [Full Text] [Related]

  • 3. Quadrivalent human papillomavirus vaccine.
    Barr E, Tamms G.
    Clin Infect Dis; 2007 Sep 01; 45(5):609-7. PubMed ID: 17682997
    [Abstract] [Full Text] [Related]

  • 4. [Vaccination against HPV in adults].
    Gil Á.
    Rev Esp Quimioter; 2009 Nov 01; 22 Suppl 1():22-5. PubMed ID: 20084345
    [No Abstract] [Full Text] [Related]

  • 5. Gardasil: Introducing the new human papillomavirus vaccine.
    McLemore MR.
    Clin J Oncol Nurs; 2006 Oct 01; 10(5):559-60. PubMed ID: 17063609
    [Abstract] [Full Text] [Related]

  • 6. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine.
    Joura EA, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch X, Dillner J, Kurman RJ, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Lupinacci LC, Giacoletti KE, Lu S, Vuocolo S, Hesley TM, Haupt RM, Barr E.
    Vaccine; 2008 Dec 09; 26(52):6844-51. PubMed ID: 18930097
    [Abstract] [Full Text] [Related]

  • 7. [Vaccination against human papillomavirus. Implementation and efficacy against cervical cancer control].
    Bégué P, Henrion R, Blanc B, Girard M, Sancho-Garnier H.
    Bull Acad Natl Med; 2007 Dec 09; 191(9):1805-16; discussion 1816-7. PubMed ID: 18663976
    [Abstract] [Full Text] [Related]

  • 8. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.
    Jenkins D.
    Gynecol Oncol; 2008 Sep 09; 110(3 Suppl 1):S18-25. PubMed ID: 18653221
    [Abstract] [Full Text] [Related]

  • 9. Cervical cancer prevention in the era of prophylactic vaccines: a preview for gynecologic oncologists.
    Society of Gynecologic Oncologists Education Resource Panel Writing groupUniversity of Illinois, Chicago, IL, USA., Collins Y, Einstein MH, Gostout BS, Herzog TJ, Massad LS, Rader JS, Wright J.
    Gynecol Oncol; 2006 Sep 09; 102(3):552-62. PubMed ID: 16979432
    [Abstract] [Full Text] [Related]

  • 10. Human papillomavirus (HPV) vaccines: a Canadian update.
    Foerster V, Murtagh J.
    Issues Emerg Health Technol; 2007 Dec 09; (109):1-8. PubMed ID: 18062141
    [Abstract] [Full Text] [Related]

  • 11. [Human papillomavirus prophylactic vaccines: stakes and perspectives].
    Hantz S, Alain S, Denis F.
    Gynecol Obstet Fertil; 2006 Dec 09; 34(7-8):647-55. PubMed ID: 16807045
    [Abstract] [Full Text] [Related]

  • 12. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine.
    Garland SM, Steben M, Sings HL, James M, Lu S, Railkar R, Barr E, Haupt RM, Joura EA.
    J Infect Dis; 2009 Mar 15; 199(6):805-14. PubMed ID: 19199546
    [Abstract] [Full Text] [Related]

  • 13. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
    Goldie SJ, O'Shea M, Campos NG, Diaz M, Sweet S, Kim SY.
    Vaccine; 2008 Jul 29; 26(32):4080-93. PubMed ID: 18550229
    [Abstract] [Full Text] [Related]

  • 14. FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP).
    Centers for Disease Control and Prevention (CDC).
    MMWR Morb Mortal Wkly Rep; 2010 May 28; 59(20):630-2. PubMed ID: 20508594
    [Abstract] [Full Text] [Related]

  • 15. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.
    Olsson SE, Villa LL, Costa RL, Petta CA, Andrade RP, Malm C, Iversen OE, Høye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgren K, von Krogh G, Lehtinen M, Paavonen J, Tamms GM, Giacoletti K, Lupinacci L, Esser MT, Vuocolo SC, Saah AJ, Barr E.
    Vaccine; 2007 Jun 21; 25(26):4931-9. PubMed ID: 17499406
    [Abstract] [Full Text] [Related]

  • 16. Papillomavirus vaccine types 16 and 18: new drug. Cervical cancer: just another vaccine.
    Prescrire Int; 2008 Jun 21; 17(95):103-4. PubMed ID: 18623911
    [Abstract] [Full Text] [Related]

  • 17. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening.
    Arbyn M, Dillner J.
    J Clin Virol; 2007 Mar 21; 38(3):189-97. PubMed ID: 17258503
    [Abstract] [Full Text] [Related]

  • 18. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing.
    Schiffman M.
    Cancer; 2007 Jun 25; 111(3):145-53. PubMed ID: 17487850
    [Abstract] [Full Text] [Related]

  • 19. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
    Muñoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia PJ, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Huh WK, Joura EA, Kurman RJ, Majewski S, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Lupinacci LC, Giacoletti KE, Sings HL, James MK, Hesley TM, Barr E, Haupt RM.
    J Natl Cancer Inst; 2010 Mar 03; 102(5):325-39. PubMed ID: 20139221
    [Abstract] [Full Text] [Related]

  • 20. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18.
    Villa LL, Ault KA, Giuliano AR, Costa RL, Petta CA, Andrade RP, Brown DR, Ferenczy A, Harper DM, Koutsky LA, Kurman RJ, Lehtinen M, Malm C, Olsson SE, Ronnett BM, Skjeldestad FE, Steinwall M, Stoler MH, Wheeler CM, Taddeo FJ, Yu J, Lupinacci L, Railkar R, Marchese R, Esser MT, Bryan J, Jansen KU, Sings HL, Tamms GM, Saah AJ, Barr E.
    Vaccine; 2006 Jul 07; 24(27-28):5571-83. PubMed ID: 16753240
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.